• Earlier this month, MiniMed announced an expanded agreement with Abbott to commercialize Abbott’s CE‑marked dual glucose–ketone Libre Duo sensors in Europe, while Abbott’s board approved its 410th consecutive quarterly dividend of US$0.63 per share payable on August 17, 2026.
• This combination of long-running dividend continuity and first-of-its-kind dual-analyte diabetes technology underscores how Abbott is pairing cash returns with ongoing innovation in chronic disease management.
• We’ll now examine how the CE‑marked Libre Duo glucose–ketone sensors could influence Abbott’s existing investment narrative around diabetes technology.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Abbott Laboratories Investment Narrative Recap

To own Abbott today, you generally need to believe in its ability to compound value through diabetes technology, diversified healthcare earnings, and consistent cash returns via dividends. The Libre Duo glucose ketone CE Mark and MiniMed expansion primarily strengthen the existing diabetes technology story; they do not materially change the near term focus on integrating the Exact Sciences deal or the ongoing risk that competitive pressure and pricing in glucose monitoring could weigh on margins.

Among recent announcements, the approval of Abbott’s 410th consecutive quarterly dividend of US$0.63 per share stands out next to Libre Duo’s launch. Together they highlight a mix of income support and product innovation that may matter for how investors weigh short term volatility against the potential of new diabetes technologies to offset pressures in diagnostics and other segments.

Yet behind this mix of innovation and dividends, investors should be aware of the growing risk that US competitive bidding for continuous glucose monitors could...

Abbott Laboratories' narrative projects $59.6 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and about a $3.2 billion earnings increase from $6.3 billion today.

Uncover how Abbott Laboratories' forecasts yield a $117.29 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community valuations cluster between US$117.29 and US$139.84, suggesting a wide spread in how you might value Abbott. Set these views against the risk that pricing pressure in continuous glucose monitoring could constrain how much Libre Duo contributes over time, and you can see why it pays to compare several perspectives before forming a view.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 59% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.